Baynes Roy D.

DirectorTravere Therapeutics, Inc. (TVTX) · full profile →Form 4 · filed Jun 16, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$225K
Net Open-Market Flow
-$225K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 12, 2026Option exercise(M)5K$21.38$96K46K
Jun 12, 2026Sell(S)5K$50.00$225K42K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 12, 2026Option exercise(M)5K$00

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001680739-26-000014) within minutes of acceptance. Every field above traces to the original document. Verify it directly: